Daniele Pastori1, Pasquale Pignatelli2, Danilo Menichelli2, Francesco Violi2, Gregory Y H Lip3. 1. Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, United Kingdom. 2. Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy. 3. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark. Electronic address: gregory.lip@liverpool.ac.uk.
Abstract
OBJECTIVE: To investigate the impact on cardiovascular events (CVEs) in a real-world population of patients with atrial fibrillation (AF) by implementing the Atrial fibrillation Better Care (ABC: A, Avoid stroke with anticoagulation; B, better symptom management; C, Cardiovascular and comorbidity risk management) pathway. PATIENTS AND METHODS: This prospective single-center cohort study included 907 consecutive patients with nonvalvular AF on vitamin K antagonists from February 2008 to December 2016. The A, B, and C groups were defined as follows: "A" by a Time in Therapeutic Range ≥65%; "B" by a European Heart Rhythm Association (EHRA) symptom scale I-II, and "C" as optimized cardiovascular comorbidity management. Primary end point was a composite outcome of CVEs. RESULTS: During a median follow-up of 36.9 months (interquartile range [IQR] 20.0-57.5; 3022 patient-years), 118 CVEs occurred (3.9% per year; 95% confidence interval [CI], 3.2-4.7). Symptomatic patients (EHRA III-IV) had a higher risk of CVEs compared with those in EHRA I (hazard ratio [HR], 2.73, 95% CI, 1.61-4.63, P<.001). Optimally managed patients in the ABC group (n=198) had a lower risk of CVEs (1.8 [95% CI, 0.9-3.0] vs 4.5% [95% CI, 3.7-5.5] per year, P=.001) compared with those presenting with at least 1 suboptimal ABC factor (HR, 0.40, 95% CI, 0.22-0.74, P=.003). This association was evident using multivariate Cox proportional regression analysis (HR, 0.44, 95% CI, 0.24-0.80, P=.007). CONCLUSION: Integrated care management according to the ABC pathway resulted in a significantly lower rate of CVEs, suggesting a clear benefit of a holistic approach to optimize the management of patients with AF. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01882114.
OBJECTIVE: To investigate the impact on cardiovascular events (CVEs) in a real-world population of patients with atrial fibrillation (AF) by implementing the Atrial fibrillation Better Care (ABC: A, Avoid stroke with anticoagulation; B, better symptom management; C, Cardiovascular and comorbidity risk management) pathway. PATIENTS AND METHODS: This prospective single-center cohort study included 907 consecutive patients with nonvalvular AF on vitamin K antagonists from February 2008 to December 2016. The A, B, and C groups were defined as follows: "A" by a Time in Therapeutic Range ≥65%; "B" by a European Heart Rhythm Association (EHRA) symptom scale I-II, and "C" as optimized cardiovascular comorbidity management. Primary end point was a composite outcome of CVEs. RESULTS: During a median follow-up of 36.9 months (interquartile range [IQR] 20.0-57.5; 3022 patient-years), 118 CVEs occurred (3.9% per year; 95% confidence interval [CI], 3.2-4.7). Symptomatic patients (EHRA III-IV) had a higher risk of CVEs compared with those in EHRA I (hazard ratio [HR], 2.73, 95% CI, 1.61-4.63, P<.001). Optimally managed patients in the ABC group (n=198) had a lower risk of CVEs (1.8 [95% CI, 0.9-3.0] vs 4.5% [95% CI, 3.7-5.5] per year, P=.001) compared with those presenting with at least 1 suboptimal ABC factor (HR, 0.40, 95% CI, 0.22-0.74, P=.003). This association was evident using multivariate Cox proportional regression analysis (HR, 0.44, 95% CI, 0.24-0.80, P=.007). CONCLUSION: Integrated care management according to the ABC pathway resulted in a significantly lower rate of CVEs, suggesting a clear benefit of a holistic approach to optimize the management of patients with AF. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01882114.
Authors: María Asunción Esteve-Pastor; Martín Ruiz-Ortiz; Javier Muñiz; Inmaculada Roldán-Rabadán; Déborah Otero; Ángel Cequier; Vicente Bertomeu-Martínez; Lina Badimón; Manuel Anguita; Gregory Y H Lip; Francisco Marín Journal: Front Cardiovasc Med Date: 2022-05-02
Authors: Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq Journal: Europace Date: 2020-08-01 Impact factor: 5.214
Authors: Jakub Gumprecht; Magdalena Domek; Marco Proietti; Yan-Guang Li; Nidal Asaad; Wafa Rashed; Alawi Alsheikh-Ali; Mohammad Zubaid; Gregory Y H Lip Journal: J Clin Med Date: 2020-04-29 Impact factor: 4.241
Authors: Ştefan Cristian Vesa; Sonia Irina Vlaicu; Octavia Sabin; Vitalie Văcăraș; Sorin Crișan; Sabina Istratoaie; Fatuma Samantar; Daciana Elena Popa; Antonia Eugenia Macarie; Anca Dana Buzoianu Journal: Int J Environ Res Public Health Date: 2020-06-04 Impact factor: 3.390